A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 6, 2008, Pages 1019-1026

  Chiorean, E Gabriela ^a   Dragovich, Tomislav ^b   Hamm, John ^c   Langmuir, Virginia K ^d   Kroll, Stewart ^d   Jung, Donald T ^d   Colowick, Alan B ^d   Tidmarsh, George F ^d   Loehrer, Patrick J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Norton Health Care   (United States)

^d Threshold Pharmaceuticals   (United States)

Author keywords

Combination chemotherapy; Gemcitabine; Glufosfamide; Pancreatic cancer; Phase I; Targeted therapy

Indexed keywords

DIMETHOATE; GEMCITABINE; GLUFOSFAMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DIARRHEA; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INSOMNIA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DEOXYCYTIDINE; FEMALE; HALF-LIFE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHORAMIDE MUSTARDS;

EID: 41049085430     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0559-8     Document Type: Article

References (13)

1. Bookman M (2005) Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15:12-17
2. Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch G, Siamopoulos K, Tzamakou E, Rammou D, Wolf L, Walker R, Hanauske A (2000) Phase I trial of 6-h infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European organization for research and treatment of cancer early clinical studies group. J Clin Oncol 18:3535-3544
3. Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Schoffski P, Raoul J, Hess D, Selvais R, Lacombe D, Bachmann P, Fumoleau P (2003) Glufosfamide administered using a 1-h infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer 39:2334-2340
4. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sulfosfamide. Arzneimittelforschung 29:659-661
5. Burris H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M, Cripps M, Portenoy R, Storniolo A, Tarassoff P, Nelson R, Dorr F, Stephens C, Von Hoff D (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
6. Correale P, Fulfaro F, Marsili S, Cicero G, Bajardi E, Intrivici C, Vuolo G, Carli A, Caraglia M, Del Prete S, Greco E, Gebbia N, Francini G (2005) Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. Cancer Chemother Pharmacol 56:563-568
7. Giaccone G, Smit E, de Jonge M, Dansin E, Briasoulis E, Ardizzoni A, Douillard J, Spaeth D, Lacombe D, Baron B, Bachmann P, Fumoleau P, Group E-NDD (2004) Glufosfamide administered by 1-h infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur J Cancer 40:667-672
8. Heinemann V, Stemmler H, Wohlrab A, Bosse D, Losem C, Kahlert S, Rauthe G (2006) High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 57:640-646
9. Hui Y, Reitz J (1997) Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54:162-170
10. Modi S, Seidman A (2004) Single-agent gemcitabine in the treatment of advanced breast cancer. Clin Breast Cancer 4:S101-S106
11. Storer B (1989) Design and analysis of Phase I clinical trials. Biometrics 45:925-937
12. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom A, Christian M, Gwyther S (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
13. +-D-glucose cotransporter SAAT1. Proc Natl Acad Sci USA 95:2914-2919